SRPK2

Across TCGA pan-cancer cohorts, SRPK2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SRPK2 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher SRPK2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SRPK2 expression acts as an unfavorable survival marker, although some lineages such as CESC show a favorable association.

SCLC, HNSC, and LUAD are the cancer types where SRPK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
HNSC	OS	Median	III,IV	0.156	0.673	.024	12	view →
LUAD	DFS	Median	II,III,IV	0.036	0.682	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CESC	DFS	Median	II,III,IV	1.000	0.452	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SRPK2–SCLC (OS)

Open the SCLC breakdown →